Maze Therapeutics, Inc. (MAZE)
Maze Therapeutics, Inc. (MAZE)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -24,208 | -34,568 | -30,087 | -66,465 |
| Depreciation expense | 444 | 499 | 571 | 1,333 |
| Stock-based compensation expense | 7,109 | 6,073 | 3,864 | 6,463 |
| Non-cash lease expense | 831 | 804 | 787 | 1,543 |
| Accretion of discounts on marketable securities, net | 2 | 227 | 278 | NaN |
| Amortization of debt discount and debt issuance costs | 371 | NaN | NaN | NaN |
| Other items, net | 18 | 0 | 0 | 21 |
| Accounts receivable | 20,000 | NaN | NaN | NaN |
| Prepaid expenses and other current assets | -404 | 433 | 758 | 1,750 |
| Accrued expenses and other liabilities | NaN | 1,963 | 2,476 | -957 |
| Other assets | 605 | -163 | -356 | -18 |
| Accounts payable | 2,212 | -1,125 | -748 | 1,846 |
| Accrued expenses and other liabilities | -4,066 | NaN | NaN | NaN |
| Operating lease liabilities | -915 | -879 | -825 | -1,620 |
| Long-term liabilities | -706 | NaN | NaN | NaN |
| Net cash used in operating activities | -39,113 | -27,730 | -24,642 | -59,568 |
| Purchases of marketable securities | 23,632 | 120,853 | 66,815 | NaN |
| Maturities of marketable securities | 30,000 | 17,500 | NaN | NaN |
| Purchases of property and equipment | 93 | 34 | 68 | 692 |
| Net cash provided by (used) in investing activities | 6,275 | -103,387 | -66,883 | -692 |
| Proceeds from initial public offering, net of offering costs paid | NaN | 0 | 0 | 127,752 |
| Proceeds from debt issuance, net | 39,401 | NaN | NaN | NaN |
| Proceeds from private placement, net of offering costs paid | NaN | -481 | 141,748 | NaN |
| Payment of debt issuance costs | 886 | NaN | NaN | NaN |
| Proceeds from exercise of stock option awards | 4,079 | 3,426 | 2,009 | 126 |
| Proceeds from issuance of common stock under the 2025 employee stock purchase plan | NaN | 644 | 0 | 612 |
| Payment of success fee derivative | NaN | 0 | 0 | 500 |
| Payment of deferred offering costs, offering costs-Underwriting Agreement | 226 | NaN | NaN | NaN |
| Proceeds from exercise of pre-funded warrants | NaN | 1 | NaN | NaN |
| Payment of deferred offering costs, offering costs-Private Placement | 11 | NaN | NaN | NaN |
| Net cash provided by financing activities | 42,357 | 3,590 | 143,757 | 127,990 |
| Net increase in cash, cash equivalents and restricted cash | 9,519 | -127,527 | 52,232 | 67,730 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 190,335 | 317,862 | 197,900 | NaN |
| Cash, cash equivalents, and restricted cash at end of the period | 199,854 | 190,335 | 317,862 | NaN |